Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

SPECIAL REPORT

HIV / AIDS

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021

HIV / AIDS

Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure

HIV Med.

Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, Lombardi F, Emiliozzi A, Belmonti S, Antinori A, Cauda R, Di Giambenedetto S

doi: 10.1111/hiv.12759.

HIV / AIDS

Patients living with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for HCV

AIDS

Guardigni V, Toschi A, Badia L, Del Turco ER, Salsi E, Cristini F, Sighinolfi L, Fabbri G, Massari M, Cuomo G, Viale P, Verucchi G, RECHIV study group.

doi: 10.1097/QAD.0000000000002973

HIV / AIDS

Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial

HIV Med.

Hamzah L, Williams D, Bailey AC, Jones R, Ibrahim F, Musso CG, Burling K, Barbini B, Campbell L, Post FA, Fanconi-Tenofovir Alafenamide trial team.

doi: 10.1111/hiv.12819.

HIV / AIDSDrug Resistance

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients

Clin Infect Dis.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study

doi: 10.1093/cid/ciz178.

HIV / AIDS

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV

HIV Med.

Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM

doi: 10.1111/hiv.12833.

HIV / AIDS

Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?

Swiss Med Wkly.

Notter J, Bregenzer A, Vernazza P, Kahlert CR

doi: 10.4414/smw.2019.20053.

HIV / AIDS

Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study

HIV Med.

Mwasakifwa GE, Amin J, White CP, Center JR, Kelleher A, Boyd MA

doi: 10.1111/hiv.12882.

Related content

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

11e Conférence de la Société internationale sur le SIDA (IAS) 2021

Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure

Patients living with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for HCV

Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV

Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?

Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021